Results 101 to 110 of about 22,513 (247)

Pseudotumour in haemophilia A [PDF]

British Journal of Haematology, 2006
Jennifer L, Rogers, Stephan, Moll
openaire   +2 more sources

DDAVP Challenges in 170 Children With von Willebrand Disease: Response Classification Varies According to Criteria Used

Haemophilia, EarlyView.
ABSTRACT Introduction Individuals diagnosed with types 1/1C/2A/2M von Willebrand disease (VWD) typically undergo a desmopressin (DDAVP) challenge to assess therapeutic benefit. This involves measuring von Willebrand factor antigen (VWF:Ag), activity (VWF:Act; VWF:RCo/VWF:GPIbM/VWF:Ab), and coagulant factor VIII (FVIII:C) levels 0 (pre), 1, and 4‐h post‐
Michael Shu, Caroline Malcolmson, Amanda Fregonas, Tristan E. Knight, Margaret L. Rand, Cindy Wakefield, Vanessa Bouskill, Manuel Carcao   +7 more
wiley   +1 more source

Global Diagnostics of Hemophilia and Bleeding Disorders: Insights From World Federation of Hemophilia International External Quality Assessment Scheme Program 2016–2023

Haemophilia, EarlyView.
ABSTRACT Introduction Accurate laboratory diagnosis is essential for the effective management of bleeding disorders. The World Federation of Hemophilia (WFH) International External Quality Assessment Scheme (IEQAS) provides an international platform for comparative evaluation of laboratory performance.
Silmara de Lima Montalvão, Ian Jennings, Dianne P. Kitchen, Christopher Reilly‐Stitt, Glenn F. Pierce, Andreina Tovar, Jayson Martin, Assad Haffar, Steve Kitchen   +8 more
wiley   +1 more source

Real‐World Experience With Emicizumab for Haemophilia A From the Physician Perspective in a Real‐World Clinical Setting

Haemophilia, EarlyView.
ABSTRACT Introduction Emicizumab is a bispecific antibody approved for prophylaxis in people with haemophilia A (PwHA). Aim To describe from the physician perspective the characteristics and treatment experiences of PwHA receiving emicizumab. Methods The Adelphi Real World Haemophilia Disease Specific Programme is a cross‐sectional, retrospective data ...
Michael Recht, Chris Blazos, Sophie Lai, Nathan Ball, Ella Morton, Lucy Lee, Juliana M. L. Biondo, Janet S. Lee   +7 more
wiley   +1 more source

Response to Letter to the Editor: Pharmacokinetic Variability in Anti‐TFPI Therapies: Why Absolute Metrics Matter for Plasma Monitoring

Haemophilia, EarlyView.
Travis Gould, Sangeeta Raje, Hae Kyung Kim   +2 more
wiley   +1 more source

Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study

Haemophilia, EarlyView.
ABSTRACT Background Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium (HS), remains limited. Objectives To evaluate changes in HS, using point‐of‐care ultrasound and clinical examination in People with Haemophilia (PwH) switching from replacement therapy to emicizumab.
Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D'Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro   +8 more
wiley   +1 more source

Risk of Postpartum Hemorrhage in Women With Von Willebrand Disease: A Real‐World Data Analysis

Haemophilia, EarlyView.
ABSTRACT Introduction Women with von Willebrand disease (VWD) are at increased risk for postpartum hemorrhage (PPH), but contemporary United States data on maternal outcomes and real‐world peripartum treatment patterns are limited. Aim To evaluate maternal outcomes associated with claims‐recorded VWD in a national claims cohort and describe exploratory
Mayank Patel, Victor Zibara, Craig Seaman, Sruti Shiva, Nicoletta C. Machin   +4 more
wiley   +1 more source

Living With Factor VII Deficiency—A Mixed Methods Study

Haemophilia, EarlyView.
ABSTRACT Background Factor VII deficiency (FVIID) is a rare autosomal recessive disorder, resulting in potentially unpredictable and life‐threatening bleeding. The prevalence of symptomatic patients is 1 in 300,000. Treatment is mostly given following bleeding, but those with the lowest levels may be offered prophylaxis.
Simon Fletcher, Matthew Boyton, Sam Bristow, Kate Khair   +3 more
wiley   +1 more source

Journeying Towards Excellence in the Care of Patients with Haemophilia and Other Inherited Bleeding Disorders From a Developing World: Insights From Tanzania

Journal of Blood Medicine
Stella Samson Rwezaula,1– 3 Samson D Mtoba,2 Rashid A Gosse,2 Rebecca W Mwakichako,2 Abdallah Raphael Makalla,1 Martha Loiseyeki Bruckman,1 Luhongedzo Gerson Matandala,1 Linda Alphey Shao,1 Hedwiga Francis Swai,1 Michelle Sholzberg,4 Jerome Teitel,4 Amos
Rwezaula SS, Mtoba SD, Gosse RA, Mwakichako RW, Makalla AR, Bruckman ML, Matandala LG, Shao LA, Swai HF, Sholzberg M, Teitel J, Mwakigonja AR, Akinloye O   +12 more
doaj  

Physical Activity, Bleeding Incidence and Health‐Related Quality of Life, in Patients With Haemophilia A Without Inhibitors, Treated With Emicizumab: A Post‐Hoc Descriptive Analysis of the Power Study Data

Haemophilia, EarlyView.
Matteo Nicola Dario Di Minno, Berardino Pollio, Ezio Zanon, Gaetano Giuffrida, Sara Bendinelli, Raffaella Perrone, Giancarlo Castaman, the POWER study sites group   +7 more
wiley   +1 more source